Analysis of associations between polymorphic markers of the AGTR1 (A1166C), AGT (M235T), CYP11B2 (C-344T), AND ACE (I/D polymorphism) genes and the risk of developing hypotension in patients with newly diagnosed stage 1–2 hypertension after 3 weeks of pharmacotherapy with angiotensin II receptor blockers

   Objective: to determine the frequency of associations between polymorphic markers of the AGTR1 (A1166C), AGT (M235T), CYP11B2 (C-344T), ACE (I/D polymorphism) genes and the risk of developing hypotension in patients with newly diagnosed stage 1–2 hypertension after 3 weeks of pharmacotherapy with angiotensin II receptor blockers.

   Materials and methods: the study included 179 patients from the Moscow region with newly diagnosed stage 1–2 hypertension and low/moderate cardiovascular risk (CVD), of which 141 (78.8 %) were women and 38 (21.2 %) were men, aged from 32 to 69 years (mean age — 58.2 ± 6.4, median age 60 (57–63 years)). They were randomly assigned to treatment groups with valsartan or irbesartan according to CVD stratification.

   Results: no statistically significant association was found between the frequency of hypotension development and the AGTR1 A1166C genotype in patients receiving either irbesartan (p = 0.398) or valsartan (p = 0.179). No statistically significant association was found between the frequency of hypotension development and the AGT C4072T genotype in patients receiving irbesartan (p > 0.999), while the highest frequency of hypotension was observed in CC homozygotes receiving valsartan (p < 0.001). No statistically significant association was found between the frequency of hypotension development and the ACE genotype in patients receiving either irbesartan (p > 0.999) or valsartan (p = 0.149). No statistically significant association was found between the frequency of hypotension development and the CYP11B2 C344T genotype in patients receiving either irbesartan (p = 0.741) or valsartan (p = 0.14).

   Conclusion: the study results do not confirm a significant impact of the aforementioned genetic markers on the development of hypotension in response to ARB therapy.

1. Zhang Z, Yang H, Guo H. Comparative efficacy and safety of six angiotensin II receptor blockers in hypertensive patients: a network meta-analysis. Int J Clin Pharm. 2024;46(5):1034-1043. DOI: 10.1007/s11096-024-01755-5.

2. Cacabelos R, Cacabelos N, Carril JC. The role of pharmacogenomics in adverse drug reactions. Expert Rev Clin Pharmacol. 2019;12(5):407-442. DOI: 10.1080/17512433.2019.1597706.

3. Camargo AC, Matte U, Botton MR. Identification of adverse drug reactions that may be related to pharmacogenetics in a public hospital in the South of Brazil. Expert Opin Drug Saf. 2023;22(7):621-627. DOI: 10.1080/14740338.2023.2181337.

4. Zhou ZW, Chen XW, Sneed KB, Yang YX, Zhang X, He ZX, et al. Clinical association between pharmacogenomics and adverse drug reactions. Drugs. 2015;75(6):589-631. DOI: 10.1007/s40265-015-0375-0.

5. Cacabelos R, Naidoo V, Corzo L, Cacabelos N, Carril JC. Genophenotypic Factors and Pharmacogenomics in Adverse Drug Reactions. Int J Mol Sci. 2021;22(24):13302. DOI: 10.3390/ijms222413302.

6. Tsermpini EE, Skokou M, Ferentinos P, Georgila E, Gourzis P, Assimakopoulos K, et al. Clinical implementation of preemptive pharmacogenomics in psychiatry: Τhe “PREPARE” study. Psychiatriki. 2020;31(4):341-351. DOI: 10.22365/jpsych.2020.314.341.

7. Ross CJ, Visscher H, Sistonen J, Brunham LR, Pussegoda K, Loo TT, et al. The Canadian Pharmacogenomics Network for Drug Safety: a model for safety pharmacology. Thyroid. 2010;20(7):681-687. DOI: 10.1089/thy.2010.1642.

8. Rebrova E.V., Shikh E.V. Effect of insertion/deletion polymorphism of angiotensin-converting enzyme gene on efficacy of antihypertensive therapy with angiotensin II receptor blockers. Pharmacy & Pharmacology. 2023;11(6):494-508. (In Russ.) DOI: 10.19163/2307-9266-2023-11-6-494-508

9. Rebrova E.V., Shikh E.V. The effect of the M235T polymorphism of the angiotensinogen gene on the office blood pressure during therapy with angiotensin II receptor blockers. Rational Pharmacotherapy in Cardiology. 2024;20(5):506-513. (In Russ.) DOI: 10.20996/1819-6446-2024-3067

10. Johnson JA, Caudle KE, Gong L, Whirl-Carrillo M, Stein CM, Scott SA, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update. Clin Pharmacol Ther. 2017;102(3):397-404. DOI: 10.1002/cpt.668

11. Karnes JH, Rettie AE, Somogyi AA, Huddart R, Fohner AE, Formea CM, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and HLA-B Genotypes and Phenytoin Dosing: 2020 Update. Clin Pharmacol Ther. 2021;109(2):302-309. DOI: 10.1002/cpt.2008

12. Yasar U, Forslund-Bergengren C, Tybring G, Dorado P, Llerena A, Sjöqvist F, et al. Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype. Clin Pharmacol Ther. 2002;71(1):89-98. DOI: 10.1067/mcp.2002.121216